


CBL Antibody (R31505)


Catalog No.	Formulation	Size
R31505	0.5mg/ml if reconstituted with 0.2ml sterile DI water	100 ug

Bulk quote request


Availability	1-3 business days
Species Reactivity	Human
Format	Antigen affinity purified
Clonality	Polyclonal (rabbit origin)
Isotype	Rabbit IgG
Purity	Antigen affinity
Buffer	Lyophilized from 1X PBS with 2.5% BSA and 0.025% sodium azide
Gene ID	867
Applications	Western Blot : 0.5-1ug/ml Immunohistochemistry (FFPE) : 1-2ug/ml Immunofluorescence : 2-4ug/ml Flow Cytometry : 1-3ug/million cells
Limitations	This CBL antibody is available for research use only.




IHC staining of FFPE human intestinal cancer with CBL antibody. HIER: boil tissue sections in pH6, 10mM citrate buffer, for 20 min and allow to cool before testing.



Western blot testing of human 1) HL60, 2) K562, 3) Raji, 4) PC-12 and 5) Ana-1 cell lysate with CBL antibody. Expected molecular weight: 100-120 kDa.



Immunofluorescent staining of FFPE human U-2 OS cells with CBL antibody. HIER: boil tissue sections in pH6, 10mM citrate buffer, for 20 min and allow to cool before testing.



Flow cytometry testing of human A549 cells with CBL antibody at 1ug/million cells (blocked with goat sera); Red=cells alone, Green=isotype control, Blue= CBL antibody.

Description

CBL (Cbl proto-oncogene) is also known as C-CBL, RNF55, CBL2 and E3 ubiquitin protein ligase. CBL is mapped to chromosome 11q23.3-qter by molecular characterization of the breakpoints in 2 somatic cell hybrids. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes(E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder.

Application Notes

The stated application concentrations are suggested starting amounts. Titration of the CBL antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Immunogen

Human partial recombinant protein (AA 556-906) was used as the immunogen for this CBL antibody.

Storage

After reconstitution, the CBL antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.